
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday
With big questions still hanging over the fate of the vaccines and drugs now in late-stage development for Covid-19, Boehringer Ingelheim is pulling one of its early-stage drugs into a Phase II trial to see if it can help some of the most severely afflicted patients.
Put through a safety study last year, researchers have been intrigued by the potential of BI 764198 — a TRPC6 inhibitor — as a treatment for acute respiratory distress syndrome (ARDS), which can cause immense damage and death for patients exposed to the virus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.